Notice of Information Clarifying Department of Defense Terminology for RFA-AT17-001 "NIH-DoD-VA Pain Management Collaboratory – Pragmatic Clinical Trials Demonstration Projects" (UG3/UH3)

Notice Number: NOT-AT-17-004

Key Dates
Release Date: February 6, 2017

Related Announcements

Issued by
National Center for Complementary and Integrative Health (NCCIH)
Department of Defense (DoD)
Department of Veterans Affairs (VA)

Office of the Assistant Secretary of Defense for Health Affairs (OASD/HA)
Clinical Rehabilitation Medicine Research Program (CRMPR)
Military Operational Medicine Research Program (MOMRP)
VA Office of Research and Development (ORD)


The purpose of this Notice is to provide revised and additional information related to DoD specific guidelines and award phases.

1. The General Guidelines for Awards Funded by the Department of Defense as referenced in the original funding opportunity announcement have been updated since the FOA was published.  The updated information can be found in the link listed in the FOA:

2. The following is DoD specific guidance regarding the phases of research of the award:

The terms UG3 and UH3 are mechanisms used by the NIH.  For translational purposes, awards funded by the DoD will refer to the UG3 mechanism as Increment 1 and UH3 as Increment 2. The DoD will make an Increment 2 award based on progress towards completion of Increment 1 milestones. The Award Project Period is a term used by the NIH. For translational purposes, awards funded by the DOD will refer to the period of performance (POP) Thus, the requirements for Increment 1 and Increment 2, including the inclusion of milestones and time limits, is the same as those for the UG3 and UH3, respectively. Similarly, all the reporting requirements for Increment 1 as well as Increment 2 awards will be same as the UG3/UH3 reporting requirements described in RFA-AT-17-001.


Please direct all inquiries to:

Dave Ruane
United States Army Medical Research Acquisition Activity (USAMRAA)
Telephone 301-619-1156